Single versus tandem autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma and high-risk cytogenetics. A retrospective, open-label study of the PETHEMA/Spanish Myeloma Group (GEM).

Autor: Villalba A; Hematology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain., Gonzalez-Rodriguez AP; Hematology Department, Hospital Universitario Central de Asturias-HUCA Oviedo, Oviedo, Spain., Arzuaga-Mendez J; Hematology Department, Grupo de Cáncer Hematológico, Biocruces Bizkaia Health Research Institute, Hospital Universitario Cruces, Barakaldo, Spain., Puig N; Hematology Department, Hospital Universitario de Salamanca (HUSAL), IBSAL, IBMCC (USAL-CSIC), CIBERONC, Salamanca, Spain., Arnao M; Hematology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain., Arguiñano JM; Hematology Department, Complejo Hospitalario de Navarra, Pamplona, Spain., Jimenez M; Hematology Department, Hospital Universitario Dr. Peset, Valencia, Spain., Canet M; Hematology Department, Hospital Universitari Mútua Terrasa, Terrasa, Spain., Teruel AI; Hematology Department, Hospital Clínico Universitario, Valencia, Spain., Sola M; Hematology Department, Hospital Universitario Morales Meseguer, Murcia, Spain., Díaz FJ; Hematology Department, Hospital Universitario de Burgos, Burgos, Spain., Encinas C; Hematology Department, Hospital General Universitario Gregorio Marañón (HGUGM), IiSGM, Madrid, Spain., Garcia A; Hematology Department, Hospital Universitari Arnau de Vilanova, Lleida, Spain., Rosiñol L; Hematology Department, Hospital Clinic, Barcelona, Spain., Suárez A; Hematology Department, Hospital de Gran Canaria Doctor Negrín, Las Palmas de Gran Canarias, Municipality of Las Palmas, Spain., Gonzalez MS; Hematology Department, H. Clínico Universitario Santiago de Compostela, La Coruña, Spain., Izquierdo I; Hematology Department, Hospital Universitario Miguel Servet, Zaragoza, Spain., Hernández MT; Hematology Department, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain., Infante MS; Hematology Department, Hospital Universitario Infanta Leonor, Madrid, Spain., Sánchez MJ; Hematology Department, Hospital Universitario Lucus Augusti, Lugo, Spain., Sampol A; Hematology Department, Hospital Universitari Son Espases, Palma de Mallorca, Spain., de la Rubia J; Hematology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain.; Hematology Department, Universidad Católica 'San Vicente Mártir', Valencia, Spain.; CIBERONC CB16/12/00284, Valencia, Spain.
Jazyk: angličtina
Zdroj: Leukemia & lymphoma [Leuk Lymphoma] 2022 Dec; Vol. 63 (14), pp. 3438-3447. Date of Electronic Publication: 2022 Sep 20.
DOI: 10.1080/10428194.2022.2123229
Abstrakt: Tandem ASCT has been suggested as a valid approach to improve the prognosis of patients with MM and HR cytogenetic. In this observational, retrospective study, 213 patients with newly diagnosed MM and HR cytogenetic in 35 hospitals from the Spanish Myeloma Group underwent single or tandem ASCT between January 2015 and December 2019 after induction with VTD/VRD. HR cytogenetic was defined as having ≥1 of the following: del17p, t (4;14), t (14;16) or gain 1q21. More patients in the tandem group had R-ISS 3 and >1 cytogenetic abnormality at diagnosis. With a median follow-up of 31 months (range, 10-82), PFS after single ASCT was 41 months versus 48 months with tandem ASCT ( p  = 0.33). PFS in patients with del17p undergoing single ASCT was 41 months, while 52% of patients undergoing tandem ASCT were alive and disease free at 48 months. In conclusion, tandem ASCT partly overcomes the bad prognosis of HR cytogenetic.
Databáze: MEDLINE
Nepřihlášeným uživatelům se plný text nezobrazuje